The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Long-term responders from the Phase III DREAMM-7 study of Bela-Vd versus Dara-Vd in R/R myeloma
Vania Hungria, MD, PhD, Santa Casa Medical School and Clinica São Germano, São Paulo, Brazil, discusses the results of a post-hoc analysis of long-term responders from the Phase III DREAMM-7 study (NCT04246047), comparing belantamab mafodotin plus bortezomib and dexamethasone (Bela-Vd) to daratumumab plus bortezomib and dexamethasone (Dara-Vd) in patients with relapsed/refractory multiple myeloma (RRMM). The analysis demonstrated that long-term responders had deeper responses and higher rates of measurable residual disease (MRD) negativity with Bela-Vd, corresponding to higher progression-free survival (PFS) rates. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
